Newfeed

FORT LEE, N.J., March 1, 2024 /PRNewswire/ — Mezzion Pharmaceuticals is a rare disease company conducting the confirmatory pivotal phase 3 clinical trial in Fontan subjects: The Fontan Udenafil Exercise Longitudinal Assessment Trial- 2, or FUEL-2 trial. The company is pleased to announce Dr. R

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: